Market Access News | pharmaphorum

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

AZ closes on FDA verdict on tremelimumab in liver cancer

AstraZeneca's anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results.

News

Closeup of X-ray photography of human brain

Biogen pulls EU application for Alzheimer's drug Aduhelm

Biogen has given up on seeking approval for its Alzheimer's disease therapy Aduhelm in the EU, saying that discussions with EU regulators had made it clear the current data for the drug is

News

Ampio slumps as FDA delivers knee osteoarthritis shock

Ampio Pharma's candidate therapy for knee osteoarthritis has been knocked back by the FDA, which will likely now require a new clinical trial of the drug before it will consider a review.

News

Gilead wins court order against fraudsters targeting HIV pro...

Gilead has won a crucial court order in a wide-ranging lawsuit against a network of clinics, prescribers, medical labs and pharmacies in Florida that it claims have been making fraudulent r

News

Teva's long-acting schizophrenia drug rejected by FDA

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone

News

GSK goes for gold as FDA starts review of daprodustat

GlaxoSmithKline says the FDA has started its review of daprodustat for anaemia associated with chronic kidney disease (CKD), as it strives to succeed where two other rivals in the HIF-PHI c

AZ closes on FDA verdict on tremelimumab in liver cancer

Biogen pulls EU application for Alzheimer's drug Aduhelm

Ampio slumps as FDA delivers knee osteoarthritis shock

Gilead wins court order against fraudsters targeting HIV pro...

Teva's long-acting schizophrenia drug rejected by FDA

GSK goes for gold as FDA starts review of daprodustat

FDA starts review of Regeneron's drug for rare disease FOP

How to meet your physicians where they are online

News

Editor's Picks